Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04127578 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

A Phase 1 study of Parkinson Disease, sponsored by Prevail Therapeutics.

Active
Registry status
Phase 1
Development phase
32
Enrollment target
15
Study locations

NCT04127578: Active Phase 1 study of Parkinson Disease, sponsored by Prevail Therapeutics.

NCT04127578 is a Phase 1 study of Parkinson Disease that is active but no longer recruiting, run by Prevail Therapeutics. The registered enrollment target is 32 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04127578, a Phase 1 study of Parkinson Disease, is active but no longer recruiting, sponsored by Prevail Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
15
Study locations

Study Summary

Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG Sirolimus
  • DRUG Methylprednisolone
  • BIOLOGICAL LY3884961

Study Locations (15)

Other

  • Shaare Zedek Medical Center, 12 Shmuel Biet Street - Jerusalem
  • Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000 - Jerusalem
  • Sheba Medical Center, Tel Hashomer - Ramat Gan
  • Tel Aviv Sourasky Medical Center, 6 Weizmann St. - Tel Aviv

Florida

  • K2 Medical Research, 101 Southhall Lane, Suite 150 - Maitland
  • PPD, 100 West Gore Street, Suite 202 - Orlando

New York

  • Mount Sinai Beth Israel, 10 Union Square East, Suite 5H - New York
  • Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street - New York

Arizona

  • Mayo Clinic, 13400 E. Shea Boulevard - Scottsdale

California

  • Esperanza Clinical, 25220 Hancock Avenue - Murrieta

Colorado

  • Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510 - Englewood

Illinois

  • Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor - Chicago

Minnesota

  • Mayo Clinic, 200 First Street SW - Rochester

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2020-01-03
Est. Completion 2030-12-31
Phase Phase 1
Prevail Therapeutics

5 total trials

What the registry record for NCT04127578 still lists

NCT04127578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.

NCT04127578 lists 15 locations in 10 states (Other, Florida, New York).

Frequently Asked Questions

What is clinical trial NCT04127578 about?

NCT04127578 is a clinical study titled "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)". Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884...

What is the current status of trial NCT04127578?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-01-03. Estimated completion is 2030-12-31.

What conditions does trial NCT04127578 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT04127578?

The interventions under investigation include: Sirolimus (DRUG), Methylprednisolone (DRUG), LY3884961 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04127578?

This trial is sponsored by Prevail Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04127578 being conducted?

This trial has 15 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04127578's enrollment target sits among peer trials

32 200th of 297 higher than 94 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04127578, the US trial registry maintained by the National Library of Medicine. NCT04127578 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.